Trial Profile
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier's Disease or Hailey-Hailey Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs ACB2003.4 (Primary)
- Indications Keratosis follicularis; Pemphigus; Skin disorders
- Focus Adverse reactions
- Sponsors Dermecular Therapeutics
- 02 Apr 2022 Status changed from recruiting to completed.
- 28 Jun 2018 New trial record